National List Of Essential Medicines Of India 2011 PDF

National List of Essential Medicines of India 2011 Page 1 of 123  TABLE OF CONTENTS PREAMBLE........................................................................................................................

National List of Essential Medicines of India 2011 Page 1 of 123  TABLE OF CONTENTS PREAMBLE...................................................................................................................................... 4 EXECUTIVE SUMMARY................................................................................................................... 6 Salient features of NLEM 2011:............................................................................................................ …..11 The meetings/deliberations of core committee/ National consultation meetings held for preparing the National List of Essential Medicines 2011............................................................. 12 PROCESS ADOPTED FOR REVISION OF NLEM.............................................................................. 13 POTENTIAL USES OF NLEM........................................................................................................... 15 EXPERTS WHO PARTICIPATED IN PREPARING NLEM- 2011.......................................................... 16 MEDICINES ADDED IN THE NLEM 2011....................................................................................... 27 MEDICINES DELETED FROM NLEM 2003...................................................................................... 29 NATIONAL LIST OF ESSENTIAL MEDICINES 2011.......................................................................... 32 Section: 1 – Anesthesia................................................................................................................. 32 Section: 2 - Analgesics , Antipyretics, Nonsteroidal Anti-inflammatory Medicines, Medicines used to treat Gout and Disease Modifying Agents used in Rheumatoid Disorders................... 34 Section: 3 – Antiallergics and Medicines used in Anaphylaxis..................................................... 35 Section: 4 - Antidotes and Other Substances used in Poisonings................................................ 36 Section: 5 – Anticonvulsants/ Antiepileptics................................................................................ 37 Section: 6 – Anti-infective Medicines........................................................................................... 38 Section: 7 –Antimigraine medicines............................................................................................. 45 Section: 8 –Antineoplastic, immunosuppressives and medicines used in palliative care........... 46 Section: 9 –Antiparkinsonism medicines...................................................................................... 49 Section: 10 –Medicines affecting the blood................................................................................. 50 Section: 11 –Blood products and Plasma substitutes................................................................... 51 Section: 12 –Cardiovascular medicines........................................................................................ 52 Section: 13 –Dermatological medicines (Topical)......................................................................... 55 Section: 14 –Diagnostic agents..................................................................................................... 57 Section: 15 –Disinfectants and antiseptics................................................................................... 58 Section: 16 –Diuretics................................................................................................................... 59 Page 2 of 123 Section: 17 – Gastrointestinal medicines..................................................................................... 60 Section: 18 –Hormones, other endocrine medicines and contraceptives................................... 63 Section: 19 Immunologicals.......................................................................................................... 66 Section: 20 – Muscle Relaxants (Peripherally acting) and Cholinesterase Inhibitors.................. 68 Section: 21 – Ophthalmological Preparations.............................................................................. 69 Section: 22 – Oxytocics and Antioxytocics.................................................................................... 70 Section: 23 – Peritoneal Dialysis Solution..................................................................................... 72 Section: 24 – Psychotherapeutic Medicines................................................................................. 72 Section: 25 – Medicines acting on the respiratory tract.............................................................. 74 Section: 26 – Solutions correcting water, electrolyte and acid-base disturbances..................... 75 Section: 27 – Vitamins and Minerals............................................................................................ 76 Alphabetical List of Medicines – Therapeutic area wise.............................................................. 77 Alphabetical List of Medicines in NLEM 2011............................................................................... 94 List of Medicines in NLEM 2011 – Category Wise...................................................................... 108 Page 3 of 123  PREAMBLE Essential medicines are those that satisfy the priority healthcare needs of majority of the population. The essential medicines list needs to be country specific addressing the disease burden of the nation and the commonly used medicines at primary, secondary and tertiary healthcare levels. The medicines in National List of Essential Medicines (NLEM) should be available at affordable costs and with assured quality. The medicines used in the various national health programmes, emerging and reemerging infections should be addressed in the list. The Government of India, Ministry of Health & Family Welfare (MOHFW) is mandated to ensure the quality healthcare system by assuring availability of safe and efficacious medicines for its population. The primary purpose of NLEM is to promote rational use of medicines considering the three important aspects i.e. cost, safety and efficacy. Furthermore it promotes prescription by generic names. Healthcare delivery institutions, health insurance bodies, standards setting institutions for medicines, medicine price control bodies, health economists and other healthcare stakeholders will be immensely benefitted in framing their policies. Page 4 of 123 The NLEM 2011 has been prepared after several rounds of wide consultations with experts of different disciplines from different parts of the country and from various organizations. The NLEM is a dynamic document and feedback from all stakeholders is welcome which will help in its revision at regular basis. The core committee of NLEM 2011 would like to place on record its appreciation for the subject experts who made a significant contribution in revision and updating the list of essential medicines of India. Page 5 of 123  EXECUTIVE SUMMARY The National list of essential medicines is one of the key instruments in balanced healthcare delivery system of a country which inter alia includes accessible, affordable quality medicine at all the primary, secondary, tertiary levels of healthcare. Realizing this GOI, MOHFW decided to have its own essential medicines list. The first National List of Essential Medicines of India was prepared and released in 1996. This list was subsequently revised in 2003. To address the issues of changing disease prevalence, treatment modalities, introduction of newer medicines and identification of unacceptable risk-benefit profile as well as therapeutic profile of some medicines, the GOI, MOHFW considered the need for updating the NLEM. Revision of NLEM was also based on the two important national reference documents i.e., Indian Pharmacopeia 2010 and National Formulary of India, 4th Edition, 2010. While the former deals with the standards of identity, purity and strength of medicines the later provides the information on rational use of medicines particularly for healthcare professionals. Page 6 of 123 In order to revise the NLEM 2003, a core committee was constituted vide order no: 12-01/ Essential Medicines/ 08-DC dated 6th July 2010 GOI, MOHFW with following members.  Prof. Y. K. Gupta, Head, Department of Pharmacology, All India Institute of Medical Sciences, New Delhi  Prof. S.K. Sharma, Head, Department of Medicine, All India Institute of Medical Sciences, New Delhi  Dr. T.S. Sidhu, Medical Superintendent, Dr. Ram Manohar Lohia Hospital, New Delhi  Dr. A. K. Harit (Chief Medical Officer) representing DDG (M), Dte. GHS, Ministry of Health & Family Welfare, New Delhi  Dr. D. Kanungo, Addl. DG (Stores) Dte. GHS, Ministry of Health & Family Welfare, New Delhi  Dr. Chander Shekhar, Scientist F, Indian Council of Medical Research, New Delhi  Dr. Sukarma S. Tanwar, National AIDS Control Organization, New Delhi  Mr. V. K. Tyagi, Deputy Industrial Advisor, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, New Delhi Page 7 of 123   Dr. G. N. Singh, Secretary-cum-Scientific Director, Indian Pharmacopoeia Commission, Ghaziabad  Dr. Surinder Singh, Drugs Controller General (India), Dte.GHS, Ministry of Health & Family Welfare, New Delhi The first meeting of the core committee of NLEM was held at CDSCO on July 22, 2010. The meeting was initiated by DCGI, Dr. Surinder Singh, Dr. Y. K. Gupta, Professor & Head, Department of Pharmacology, AIIMS, New Delhi was unanimously nominated as chairman of the Committee. During this meeting the core committee was informed that the CDSCO had already taken an initiative in this direction and organized a workshop entitled “Expert Group Meeting on Revision and Updating of the National List of Essential Medicines” on September 16, 2009 in collaboration with Department of Pharmacology, AIIMS and WHO India Office. The workshop was attended by representatives from the following: CDSCO, Ministry of Health; WHO; All India Institute of Medical Sciences, New Delhi; Indian Pharmacopoeia Commission; Indian Council of Medical Research and experts of different disciplines from leading medical and pharmacy institutions of the country. The issue of updating NLEM was also deliberated in a dedicated session during the Annual Conference of Indian Pharmacological Society, December 2009 at Page 8 of 123 Kolkata and the session was chaired by Prof. Y K Gupta, AIIMS and Dr. K Weerasuriya, WHO-SEARO. The core committee took note of the proceedings of these two meetings while revising the NLEM. In this core committee meeting it was deliberated that although WHO has prepared an updated list of “Essential Medicines”, it cannot be adopted as such. The NLEM of India should be country specific considering the disease prevalence, cost effectiveness of Medicines etc in the country. In the meeting the criteria for inclusion/ deletion of medicines were developed and a road map for the revision and updating of NLEM, 2003 was drawn. Sh. V. K. Tyagi from Department of Pharmaceuticals (DoP), Ministry of Chemicals & Fertilizers emphasized the importance of NLEM in view of the directions of the Hon’ble Supreme Court of India. He also mentioned that DoP may rely on the NLEM prepared by MOH &FW for price fixation. During the meeting it was felt that opinion/views may be taken from across the country by organizing brainstorming regional workshops. However, considering the logistics and time constraints it was decided that a National consultation meet should be organized in Delhi inviting experts from various specialties and from different parts of the country. Page 9 of 123 Accordingly “National Consultation Meet for Revision of National List of Essential Medicines” was organized by Department of Pharmacology, AIIMS & Central Drugs Standard Control Organization (CDSCO), Ministry of Health and Family Welfare on December 3-4, 2010. The meet was supported by WHO India office. Experts from different disciplines from medical and pharmaceutical institutes, hospitals from across the country and concerned government agencies participated. After initial briefing, four groups were formed according to therapeutic areas. The groups were asked to specifically give the reasons/evidence which guided their decision regarding addition/deletion/alteration. Subsequently the recommendations of the individual groups were discussed in the open house. Thereafter the draft recommendations of the Workshop were prepared with general consensus. The recommendations of the Workshop were further deliberated upon by the Expert Core Committee on 4th Jan 2011 and 31st Jan 2011 at CDSCO. The revised NLEM 2011 has thus been prepared. The Expert Core Committee recommended that all the medicines which are being provided under various National Health Programmes are considered as essential medicines. Page 10 of 123  Salient features of NLEM 2011: The medicines have been categorized according to therapeutic area. Therefore it is possible that a medicine with more than one indication appears in more than one category. The issue of mentioning the strength of the medicine dose was deliberated. The committee took the considered view that the strength should be mentioned in the NLEM. For essentiality of requirement the medicines have been categorized as follows: - P, S and T denote essentiality at Primary, Secondary and Tertiary levels respectively while P, S, T (U in NLEM 2003) indicates essentiality at all the levels. A total of 348 medicines (excluding repetitions) are present in NLEM 2011. In the NLEM 2011, 181 medicines fall under the category of P, S and T, 106 medicines fall under the category of S, T while 61 medicines are categorized as T only. In comparison to NLEM 2003, number of medicines deleted is 47 and 43 medicines have been added. Page 11 of 123 The meetings/deliberations of core committee/ National consultation meetings held for preparing the National List of Essential Medicines 2011 Core Committee Meetings 1. The first meeting was held at CDSCO, FDA Bhawan on July 22, 2010 2. The second meeting was held at CDSCO, FDA Bhawan on January 4, 2011 3. The third meeting was held at CDSCO , FDA Bhawan on 31st Jan,2011 National Consultation Meetings 1. The first consultation meet was held on September 16, 2009 at Department of Pharmacology, AIIMS, New Delhi 2. The second National consultation meet was held on December 3-4, 2010 at Department of Pharmacology, AIIMS, New Delhi Other Deliberations: 1. A dedicated session on National Essential Medicine List was organized during 42nd Annual conference of Indian Pharmacological Society, on 11th December, 2009 at Swabhumi, Kolkata Page 12 of 123  PROCESS ADOPTED FOR REVISION OF NLEM National List of Essential Medicines 2003 (Base document) Consultation meetings with Experts Deliberation on Evidence based criteria for addition and deletion of medicines from the NLEM Therapeutic area wise group discussion (Group composition: Clinicians, Pharmacologists, Pharmacists, Scientists and Regulators) REVISION PROCESS contd… Page 13 of 123  Presentation by groups in open house discussion Resource Materials: Resource Support: WHO Model List of Essential Scientists, Senior Residents, Medicines 2010, WHO model formulary, Junior Residents and PhD National Formulary of India Scholar of Dept of 2010 (Pre print Version), Pharmacology, AIIMS, New Textbooks of Pharmacology, Delhi Internal Medicine, Drug compendia, Indian Pharmacopoeia, Internet facility Deliberations/ discussion and reasoning for additions/ deletions/modifications Draft recommendations for NLEM Consideration and adoption of NLEM by the Core Committee Page 14 of 123  POTENTIAL USES OF NLEM The concept of essential medicines, first introduced by WHO in 1977, has now been adopted by many countries, non-governmental organizations and international non-profit supply agencies. The list is considered to include the most cost-effective medicines for a particular indication. It is developed in concordance with the standard treatment guidelines keeping in mind the healthcare needs of the majority of the population. Careful selection of a limited range of essential medicines results in a higher quality of care, better management of medicines and more cost-effective use of health resources. The list of essential medicines guides the hospital drug policies, procurement and supply of medicines in public sector, medicine cost reimbursement and medicine donations. It helps in monitoring the pricing of medicines. The list serves as a reference document for correct dosage form and strength for prescribing. Preference is given to single drug formulations as opposed to fixed dose combinations where appropriate. Hence use of NLEM is expected to improve prescribing practices as well as the health outcomes. The appropriate use of medicines selected in the NLEM promotes rational use of medicines. Such rational use of medicines, especially antimicrobial drugs, reduces development of drug resistance. The list also serves as a reference for assessing the healthcare access of the populace. Lastly, NEML serves as a tool for public education and training of healthcare providers. Page 15 of 123  EXPERTS WHO PARTICIPATED IN PREPARING NLEM- 2011 Meeting Meeting Specialization/ held on held on S.No NAME AFFILIATION Department September December 16, 2009 3-4, 2010 Joint Drug Controller (India), 1. A B RAMTEKE CDSCO, FDA Bhawan, Regulatory Body   Kotla Road, New Delhi Assistant Drug Controller, 2. A K PRADHAN CDSCO, FDA Bhawan, Regulatory Body   Kotla Road, New Delhi Associate Professor, 3. ANANT MOHAN Dept. of Medicine, Medicine   AIIMS, New Delhi Professor, 4. ARTI KAPIL Dept of Microbiology, Microbiology   AIIMS, New Delhi Dean and Director Professor ARUN K Department of ENT 5. AGARWAL Maulana Azad Medical College ENT --  New Delhi Technical Officer, 6. ASEEM SAHU CDSCO, FDA Bhawan, Regulatory Body   Kotla Road, New Delhi Professor, 7. BALRAM Dept. of Cardiology, Cardiology  --- BHARGAVA AIIMS, New Delhi Page 16 of 123  Meeting Meeting Specialization/ held on held on S.No NAME AFFILIATION Department September December 16, 2009 3-4, 2010 Associate Professor, 8. BIKASH MEDHI Department of Pharmacology, Pharmacology   PGIMER, Chandigarh Asst. Professor BISWA MOHAN 9. PADHY Department of Pharmacology Pharmacology √  HIMSR, Jamia Hamdard Professor and Head, 10. C D TRIPATHI Dept. of Pharmacology, Pharmacology  -- Vardhman Medical College and Hospital, New Delhi Medical Superintendent, 11. D K SHARMA AIIMS, Medicine   New Delhi Addl. DG (Stores), DGHS, MOHFW, Nirman 12. D. KANUNGO Bhawan, MOHFW --  New Delhi Professor, 13. DEEPIKA DEKA Dept. of Obstetrics & Gynaecology  -- Gynaecology, AIIMS, New Delhi. Prof & Head G Dept. of Clinical Pharmacy 14. PARTHASARATHI JSS College of Pharmacy and Pharmacy ---  JSS Medical College Mysore Technical Officer, 15. GAURAV KUMAR CDSCO, FDA Bhawan, Regulatory Body   Kotla Road, New Delhi Page 17 of 123  Meeting Meeting Specialization/ held on held on S.No NAME AFFILIATION Department September December 16, 2009 3-4, 2010 Secretary-cum-Scientific Director, 16. GN SINGH Indian Pharmacopeia Pharmacy , --  Commission, Govt of India , Ghaziabad Assistant Professor, 17. JAGRITI BHATIA Dept. of Pharmacology, Pharmacology  √ AIIMS, New Delhi Principal Scientist, 18. JAI PRAKASH Indian Pharmacopoea Pharmacy   Commission , Govt of India Ghaziabad Jt. Advisor JANARDAN Department of AYUSH, 19. PANDEY MOHFW ---  Ministry of health and Family Welfare ,Govt of India Associate Professor, 20. JATINDER KATYAL Dept. of Pharmacology, Pharmacology   AIIMS, New Delhi Department of Hospital Hospital 21. JITENDRA Administration, Administration --  AIIMS, New Delhi Asstt. Professor Department of Dermatology & K D BARMAN Dermatology 22. STD, and STD --  Maulana Azad Medical College New Delhi Assistant Professor, 23. K H REETA Dept. of Pharmacology, Pharmacology   AIIMS, New Delhi Page 18 of 123  Meeting Meeting Specialization/ held on held on S.No NAME AFFILIATION Department September December 16, 2009 3-4, 2010 Professor and Head, 24. K K PANT Dept. of Pharmacology, Pharmacology   CSM Medical College and Hospital, Lucknow Professor and Head, 25. K K SHARMA Dept. of Pharmacology, Pharmacology  --- UCMS, New Delhi Regional Adviser Essential Drugs and Medicines 26. K WEERASURIYA Policy Clinical  -- Pharmacology World Health Organization – SEARO Professor, 27. KAMAL KISHORE Dept. of Pharmacology, Pharmacology  -- AIIMS, New Delhi Professor and Head, 28. M C GUPTA Dept. of Pharmacology, Pharmacology  -- PGIMS, Rohtak, Haryana NPO Essential Drugs and Medicines Clinical 29. MADHUR GUPTA WHO country office for India Pharmacology --  Professor and Head, 30. MADHURI BEHARI Dept. of Neurology, Neurology   AIIMS, New Delhi Associate Professor, 31. MANJARI Dept. of Neurology, Neurology  -- TRIPATHI AIIMS, New Delhi Page 19 of 123  Meeting Meeting Specialization/ held on held on S.No NAME AFFILIATION Department September December 16, 2009 3-4, 2010 Director Professor MK DAGA Department of Medicine 32. Maulana Azad Medical College Medicine ---  New Delhi Department of Medicine 33. MPS CHAWLA RML Hospital, New Delhi Medicine ---  Associate Professor 34. MUKUL MATHUR Dept. of Pharmacology Pharmacology ---  SMS Medical college, Jaipur Professor, 35. N R BISWAS Dept. of Pharmacology, Clinical  -- Pharmacology AIIMS, New Delhi Professor, 36. NARESH KHANNA Dept. of Pharmacology, Pharmacology   UCMS, New Delhi NASEEM SHAH Chief, Professor and Head 37. Centre for Dental Education Dental Medicine  --- and Research AIIMS, New Delhi Associate Professor, 38. AJOY Centre for Dental Education Dental Medicine --  ROYCHAUDHURY and Research AIIMS, New Delhi Associate Professor NEENA Obstetrics and 39. MALHOTRA Department of Obstretics and gynecology ---  Gynaecology, AIIMS, New Delhi Dy. Director, Pharmacolgy 40. NEENA VALECHA National Institute of Malaria and Malaria  -√-- Research, experti Dwarka, New Delhi Page 20 of 123  Meeting Meeting Specialization/ held on held on S.No NAME AFFILIATION Department September December 16, 2009 3-4, 2010 Emeritus Scientist, 41. O P AGARWAL Indian Council of Medical Pharmacology  --- Research, New Delhi Professor, 42. P K MEDIRATTA Dept. of Pharmacology, Pharmacology   UCMS, New Delhi Department of Pharmacology Nizams Institute of Medical Clinical 43. P USHA RANI Sciences, Pharmacology ---  Hyderabad Professor & Head, 44. PRAMIL TIWARI Dept. of Pharmacy Practice, Pharmacy  --- NIPER, SAS Nagar, Mohali, Punjab Associate Professor Department of Gastroentrology 45. PRAMOD GARG Gastroenterology and Human ysician ---  Nutrition, AIIMS, New Delhi Professor and Head, 46. PRAVEEN Dept. of Emergency Medicine, Medicine   AGGARWAL AIIMS, New Delhi Director, Health 47. R C DEKA AIIMS, New Delhi. Administrator  √--- and ENT Professor , 48. R K BATRA Dept. of Anaesthesia and Anaesthesia   Intensive Care, AIIMS, New Delhi Page 21 of 123  Meeting Meeting Specialization/ held on held on S.No NAME AFFILIATION Department September December 16, 2009 3-4, 2010 Prof & Head RAJENDRA Dept of Pulmonary Medicine Pulmonary 49. PRASAD medicine ---  CSM Medical College and Hospital, Lucknow Scientist E, 50. RAJNI KAUL Indian Council of Medical Basic Scientist  --- Research, New Delhi Professor RAKESH 51. CHADDHA Department of Psychiatry Psychiatry ---  AIIMS Associate Professor, 52. RAKESH YADAV Dept of Cardiology, Cardiology   AIIMS, New Delhi Programme Officer (CST), 53. RESHU AGARWAL NACO, New Delhi Medicine ---  Associtate Professor Dr. R P Centre for Opthalmic Sciences 54. ROHIT SAXENA AIIMS Ophthalmology ---  Professor and Head, 55. S K TRIPATHI Dept. of Clinical Pharmacology, Clinical   Pharmacology School of Tropical Medicine, Kolkata, WB Associate Professor, 56. SAMEER BAKSHI Medical Oncology, IRCH, Medical   Oncology AIIMS, New Delhi Page 22 of 123  Meeting Meeting Specialization/ held on held on S.No NAME AFFILIATION Department September December 16, 2009 3-4, 2010 Professor & Head, 57. SANDEEP Department of Pharmacology, Pharmacology  --- KAUSHAL Dayanand Medical College, Ludhiana Professor & Head, 58. SANGEETA Dept of Neuropsycho Clinical   SHARMA Pharmacology, Pharmacology IHBAS, Delhi Associate Professor, Centre for Community Community 59. SANJAY KR. RAI Medicine Medicine ---  AIIMS, New Delhi. Chief Pharmacist Institute of Liver and Biliary 60. SEEMA DUBEY Sciences Pharmacy ---  New Delhi Medical Superintendent, R.P. Centre for Ophthalmic Sciences & Hospital 61. SHAKTI GUPTA Head, Dept. of Hosp. Administration   Administration, AIIMS, New Delhi Scientist, National Poision Information Centre , 62. SHARDA PESHIN Toxicology   Dept. of Pharmacology, AIIMS, New Delhi SHRIDHAR Professor and Head, 63. DWIVEDI Department of Medicine Medicine ---  UCMS, New Delhi Page 23 of 123  Meeting Meeting Specialization/ held on held on S.No NAME AFFILIATION Department September December 16, 2009 3-4, 2010 Associate Professor SHYAM SUNDER 64. SHARMA Department of Pharmacology, Pharmacology ---  NIPER, Mohali Professor 65. SK MAULIK Department of Pharmacology Pharmacology ---  AIIMS, New Delhi DDGM Community 66. SK PRADHAN DGHS, MOHFW Medicine ---  New Delhi Technical Officer, 67. SUNIL CDSCO, FDA Bhawan, Pharmacy   KULSHESTRA Regulatory Body Kotla Road, New Delhi National Professional Officer 68. SUNIL NANDRAJ (Health Systems Development), WHO  --- World Health Organization, New Delhi Assistant Professor, 69. SURENDER SINGH Dept. of Pharmacology, Pharmacy and   Pharmacology AIIMS, New Delhi Medical Superintendent, T.S. SIDHU, ENT surgeon 70. RML Hospital, and Hospital ---  Administration New Delhi TUSHAR Assistant Professor 71. AGGARWAL Department of Ophthalmology Ophthalmology ---  AIIMS, New Delhi Department of Hospital Administration, Hospital 72. U S GARG AIIMS, New Delhi Administration ---  Page 24 of 123  Meeting Meeting Specialization/ held on held on S.No NAME AFFILIATION Department September December 16, 2009 3-4, 2010 Director Professor & Head, UMA TEKUR Department of Pharmacology 73. Maulana Azad Medical College, Pharmacology ---  New Delhi Professor & Head 74. V K PAUL Department of Pediatrics Pediatrics  --- AIIMS, New Delhi Deputy Industrial Advisor, Dept. of Pharmaceuticals, Ministry of 75. V. K. TYAGI Ministry of Chemical & Chemicals & ---  Fertilisers, Fertilizers New Delhi Assistant Professor, 76. VANDANA JAIN Dept. of Pediatrics, Pediatrics  --- AIIMS, New Delhi Scientist F, 77. VIJAY KUMAR Indian Council of Medical Health  --- administrator Research, New Delhi Assistant Professor, 78. VINAY GULATI Department of Medicine, Medicine  --- AIIMS, New Delhi Professor and Head, 79. VINOD RAINA Medical Oncology, Institute Medical  --- Cancer Rotary Hospital (IRCH), Oncology AIIMS, New Delhi VISHAL KUMAR Medical Officer 80. MALHOTRA Chacha Nehru Bal Chikitsalaya Pediatrics ---  New Delhi Page 25 of 123  Meeting Meeting Specialization/ held on held on S.No NAME AFFILIATION Department September December 16, 2009 3-4, 2010 Associate Professor Department of Medicine 81. VIVEK ARYA Medicine ---  PGIMER, Dr. RML Hospital, New Delhi Professor and Head, 82. Y K GUPTA Dept of Pharmacology, Pharmacology   AIIMS, New Delhi Additional Professor YASHPAL Department of Cardiology, 83. SHARMA PGIMER, Chandigarh Cardiology ---  Senior Resident, Clinical 84. Pooja Gupta Department of Pharmacology, Pharmacology   AIIMS, New Delhi Senior Resident, Ashish Kumar Clinical 85. Kakkar Department of Pharmacology, Pharmacology --  AIIMS, New Delhi Senior Resident, Sudhir Chandra Clinical 86. Sarangi Department of Pharmacology, Pharmacology   AIIMS, New Delhi Technical Associate (PvPI) Saravana Perumal 87. S Department of Pharmacology, Pharmacy   AIIMS, New Delhi Page 26 of 123  MEDICINES ADDED IN THE NLEM - 2011 S.No. Name of the medicine 1. 25% Dextrose 2. 5-Amino salicylic Acid (5-ASA) 3. Allopurinol 4. Amoxicillin+Clavulinic acid 5. Atorvastatin 6. Betamethasone 7. Carboplatin 8. Cefixime 9. Cetrizine 10. Chlorambucil 11. Clindamycin 12. Clopidogrel 13. Dacarbazine 14. Daunorubicin 15. Diazepam 16. EMLA cream 17. Enoxaparin 18. Famotidine 19. Fentanyl 20. Filgrastim 21. Hydroxychloroquine phosphate 22. Ifosfamide 23. Imatinib Page 27 of 123  24. Ipratropium bromide 25. Leflunomide 26. Lorazepam 27. Mefloquine 28. Mesna 29. Misoprostol 30. N-acetylcysteine 31. Olanzapine 32. Oxaliplatin 33. Pantoprazole 34. Permethrin 35. Piperazine 36. Premix Insulin 30:70 injection 37. Propofol 38. Sevoflurane 39. Stavudine+Lamivudine 40. Tramadol 41. Vecuronium 42. Zidovudine+Lamivudine+Nevirapine 43. Zinc Sulfate. Page 28 of 123  MEDICINES DELETED FROM NLEM - 2003 S.No. Name of the medicine 1. Acenocoumarol 2. Aminophylline 3. Benzoic Acid + Salicylic Acid 4. Benzylpenicillin 5. Bretylium Tosylate 6. Cefuroxime 7. Centchroman 8. Chloramphenicol 9. Chlorthalidone 10. Clarithromycin 11. Clomipramine hydrochloride 12. Clonidine Hydrochloride 13. Doxapram 14. Ethyl Chloride 15. Flucytosine 16. Furazolidone 17. Gamma Benzene Hexachloride 18. Isoprenaline Hydrochloride 19. Isoxsuprine hydrochloride 20. Ketoconazole 21. Loperamide 22. Mebendazole Page 29 of 123  MEDICINES DELETED FROM NLEM - 2003 S.No. Name of the medicine 23. Menadione Sodium Sulphite 24. Mexiletine Hydrochloride 25. Nalidixic Acid 26. Niclosamide 27. Nitrazepam 28. Norfloxacin 29. Pancuronium 30. Pentazocine 31. Pethidine Hydrochloride 32. Physostigmine Salicylate 33. Procaine Benzylpenicillin 34. Prochlorperazine 35. Pyrantel Pamoate 36. Quinidine 37. Roxithromycin 38. Silver Nitrate 39. Terazosin 40. Tetracycline 41. Tetracycline Hydrochloride 42. Theophyline compounds 43. Thiacetazone + Isoniazid 44. Tinidazole 45. Trifluoperazine Page 30 of 123  MEDICINES DELETED FROM NLEM - 2003 S.No. Name of the medicine 46. Trimethoprim 47. Xylometazoline Page 31 of 123  NATIONAL LIST OF ESSENTIAL MEDICINES 2011 Section: 1 – Anesthesia 1.1 General Anesthetics and Oxygen Route of Administration/ Medicines Category Strengths Dosage Form Ether S, T Inhalation -- Halothane with vaporizer S, T Inhalation Isoflurane S, T Inhalation 10 mg / ml, Ketamine Hydrochloride P, S, T Injection 50 mg / ml Nitrous Oxide P, S, T Inhalation Oxygen P, S, T Inhalation Thiopentone Sodium S, T Injection 0.5 g, 1 g powder Added Medicines Sevoflurane T Inhalation Propofol P,S,T Injection 1% oil suspension 1.2 Local Anesthetics Route of Administration/ Medicines Category Strengths Dosage Form Bupivacaine Hydrochloride S, T Injection 0.25%, 0.5%, 0.5% to be mixed with 7.5% glucose solution Page 32 of 123  Topical Forms, 2-5%, Lignocaine Hydrochloride P, S, T Injection, 1-2%, Spinal 5% +7.5% Glucose Lignocaine Hydrochloride 1%, 2% + P, S, T Injection + Adrenaline Adrenaline1:200,000 Added Medicines EMLA cream T Cream 1.3 Preoperative Medication and Sedation for Short Term Procedures Route of Administration/ Medicines Category Strengths Dosage Form Atropine Sulphate P, S, T Injection 0.6 mg / ml Tablets 5 mg P,S,T Injection, 5 mg / ml Diazepam S, T Syrup, 2mg/5ml Suppository 5 mg 1 mg / ml Midazolam P, S, T Injection 5 mg / ml Morphine Sulphate S, T Injection 10 mg / ml Promethazine P, S, T Syrup 5 mg / 5 ml Page 33 of 123 Section: 2 - Analgesics , Antipyretics, Nonsteroidal Anti-inflammatory Medicines, Medicines used to treat Gout and Disease Modifying Agents used in Rheumatoid Disorders 2.1: Non-Opioid Analgesics, Antipyretics and Nonsteroidal Anti-inflammatory Medicines Route of Administration/ Medicines Category Strengths Dosage Form Acetyl Salicylic Acid P, S, T Tablets 325mg, 350 mg T Tablets 50 mg Diclofenac T Injection 25 mg / ml Tablets 200 mg, 400 mg Ibuprofen P, S, T Syrup 100mg/5ml P, S, T Injection 150 mg / ml P, S, T Syrup 125 mg / 5ml Paracetamol P, S, T Tablets 500 mg P, S, T Suppository 80 mg, 170 mg 2.2 Opioid Analgesics Route of Administration/ Medicines Category Strengths Dosage Form Injection 10 mg / ml S, T Morphine Sulphate Tablets 10 mg Added medicines Injection 50 mg/ml S,T Tramadol Cap 50 mg,100 mg Fentanyl S,T Injection 50μg/ml 2ml ampoule Page 34 of 123  2.3 Medicines used to treat Gout Allopurinol S, T Tablets 100 mg Colchicine S, T Tablets 0.5 mg 2.4 Disease modifying agents used in Rheumatoid disorders Azathioprine S, T Tablets 50 mg Methotrexate S,T Tablets 5mg, 7.5mg, 10mg Sulfasalazine S, T Tablets 500 mg Added medicines Hydroxychloroquine S,T Tablets 200 mg phosphate Leflunomide S,T Tablets 10mg ,20 mg tab Section: 3 – Antiallergics and Medicines used in Anaphylaxis Route of Administration/ Medicines Category Strengths Dosage Form Adrenaline Bitartrate P, S, T Injection 1 mg / ml Chlorpheniramine P, S, T Tablets 4 mg Maleate Dexchlorpheniramine P, S, T Syrup 0.5 mg / 5 ml Maleate Dexamethasone P, S, T Tablets 0.5 mg Injection 4 mg / ml Hydrocortisone Sodium P, S, T Injection 100 mg Succinate Pheniramine Maleate P, S, T Injection 22.75 mg / ml Prednisolone P, S, T Tablets 5 mg, 10 mg, 20 mg P, S, T Tablets 10 mg, 25 mg Promethazine Syrup 5 mg / 5 ml Added Medicines Cetrizine P,S,T Tablets 10mg Syrup 5 mg/ml Page 35 of 123  NLEM 2011 Section: 4 - Antidotes and Other Substances used in Poisonings 4.1: Nonspecific Route of Administration/ Medicines Category Strengths Dosage Form Activated Charcoal P,S,T Oral 4.2: Specific Route of Administration/ Medicines Category Strengths Dosage Form Atropine Sulphate P,S,T Injection 1 mg/ml Specific Antisnake venom P,S,T Injection Polyvalent Solution/ Lyophilyzed Polyvalent Serum Calcium gluconate P,S,T Injection 100mg/ml Desferrioxamine mesylate S, T Injection 500mg Methylthioninium chloride S, T Injection 10 mg / ml (Methylene blue) Penicillamine S, T Tablets or Capsules 250 mg Dimercaprol S, T Injection in oil 50 mg / ml Flumazenil T Injection 0.1 mg / ml Sodium Nitrite S, T Injection 30 mg / ml Sodium Thiosulphate S, T Injection 250 mg/ ml Naloxone P,S,T Injection 0.4mg/ml Pralidoxime Chloride(2-PAM) P,S,T Injection 25 mg/ml Added medicines: N-acetylcysteine P,S,T Injection 200 mg/ml (5 ml) Page 36 of 123  Section: 5 – Anticonvulsants/ Antiepileptics Route of Administration/ Medicines Category Strengths Dosage Form Carbamazepine P, S, T Tablets 100mg Syrup 200mg 100 mg/5ml Diazepam P,S,T Injection 5 mg / ml Magnesium sulphate S,T Injection 500 mg /ml Phenobarbitone P,S,T Tablets 30 mg,60 mg S,T Injection 200 mg/ml P,S,T Syrup 20 mg/5ml Phenytoin Sodium P,S,T Capsules or Tablets 50 mg, Syrup 100mg Injection 25mg/ml 50 mg/ml Sodium Valproate P,S,T Tablets 200 mg, Syrup 500mg 200 mg/5ml T Injection 100 mg/ml Added Medicines Lorazepam T Injection 2mg/ml Page 37 of 123  Section: 6 – Anti-infective Medicines 6.1 Anthelminthics 6.1.1 Intestinal Anthelminthics Route of Administration/ Medicines Category Strengths Dosage Form Albendazole P,S,T Tablets 400 mg Suspension 200 mg/ 5 ml Added Medicines Piperazine P,S,T Tablets 4.5 gm Solution 750mg/5ml 6.1.2 Antifilarials Route of Administration/ Medicines Category Strengths Dosage Form Diethylcarbamazine citrate P,S,T Tablets 50 mg 6.1.3 Antischistosomals and Antitrematode Medicines Route of Administration/ Medicines Category Strengths Dosage Form Praziquantel S, T Tablets 600 mg 6.2 Antibacterials 6.2.1 Beta lactam medicines Route of Administration/ Medicines Category Strengths Dosage Form Amoxicillin S,T Powder for suspension 125 mg / 5 ml Capsules 250 mg, 500 mg Capsules 250 mg, 500 mg Ampicillin P,S,T Powder for suspension 125 mg / 5 ml Injection 500 mg Page 38 of 123  P,S,T Injection Benzathine Benzylpenicillin 6 lacs, 12 lacs units Cefotaxime S, T Injection 125 mg, 250 mg 500 mg Ceftazidime S, T Injection 250mg, 1g Ceftriaxone S, T Injection 250 mg, 1 g Cephalexin P,S,T Syrup 125 mg / 5 ml Capsules 250 mg, 500 mg Cloxacillin P,S,T Capsules 250 mg, 500 mg Injection 250 mg Liquid 125mg/ 5 ml Added Medicines Amoxicillin + Clavulinic acid T Tablets 625 mg Powder for suspension 228.5mg/5ml Injection 600mg, 1.2gm Cefixime T Tablet 100, 200mg 6.2.2 Other antibacterials Route of Administration/ Medicines Category Strengths Dosage Form Amikacin S, T Injection 250 mg / 2 ml Tablets 100, 250,500mg Azithromycin S,T Suspension 100mg/5ml Injection 500mg Ciprofloxacin P,S,T Injection 200 mg /100 ml Hydrochloride Tablets 250 mg, 500 mg 80 + 400 mg, Co-Trimoxazole P,S,T Tablets 160+800 mg (Trimethoprim + Sulphamethoxazole) Suspension 40 + 200 mg / 5 ml Page 39 of 123  Doxycycline P,S,T Tablets 100 mg Erythromycin Syrup 125 mg / 5 ml Estolate P,S,T Tablets 250 mg, 500 mg Gentamicin P,S,T Injection 10 mg / ml, 40 mg / ml Metronidazole P,S,T Tablet 200mg,400mg Injection 500mg/100ml Syrup 100mg/5ml Nitrofurantoin P,S,T Tablets 100 mg Sulphadiazine S, T Tablets 500 mg Vancomycin Hydrochloride T Injection 500 mg, 1 g 6.2.3 Antileprosy medicines Route of Administration/ Medicines Category Strengths Dosage Form Clofazimine P,S, T Capsules 50 mg, 100 mg Dapsone P,S, T Tablets 50 mg, 100mg Rifampicin P,S, T Capsules or Tablets 150 mg, 300 mg 6.2.4 Antituberculosis medicines Route of Administration/ Medicines Category Strengths Dosage Form Ethambutol P,S,T Tablets 200 mg, 400 mg, 600 mg, 800 mg 50 mg, 100 mg, 300 Tablets mg Isoniazid P,S,T Syrup 100 mg/5ml Tablets 100 mg, 200 mg Ofloxacin S, T Syrup 50 mg / 5 ml 500 mg, 750 mg, 1000 Pyrazinamide P,S,T Tablets mg, 1500 mg Page 40 of 123  50 mg, 150 mg, 300 Capsules/Tablets mg,450 mg Rifampicin P,S,T Syrup 100 mg / 5 ml Streptomycin Sulphate P,S,T Injection 0.75 g, 1 g 6.3 Antifungal medicines Route of Administration/ Medicines Category Strengths Dosage Form Amphotericin B S, T Injection 50 mg Pessaries 100 mg, 200 mg, Clotrimazole P,S,T Gel 2% 50 mg, 100 mg, 150 Fluconazole mg, S, T Capsules or Tablets 200 mg Griseofulvin P,S,T Capsules or Tablets 125 mg, 250 mg Tablets 500,000 IU Nystatin P,S,T Pessaries 100,000 IU 6.4 Antiviral medicines 6.4.1 Antiherpes medicines Route of Administration/ Medicines Category Strengths Dosage Form Tablets 200 mg, 400 mg Acyclovir S, T Injection 250 mg, 500 mg Suspension 400 mg / 5 ml 6.4.2 Antiretroviral medicines 6.4.2.1 Nucleoside reverse transcriptase inhibitors Route of Administration/ Medicines Category Strengths Dosage Form Didanosine S, T Tablets 250 mg, 400 mg Page 41 of 123  Lamivudine S, T Tablets 150 mg Lamivudine + Nevirapine + 150 mg + 200 mg+ Stavudine S, T Tablets 30 mg Lamivudine + Zidovudine S, T Tablets 150 mg + 300 mg 15 mg, 30 mg, 40 Stavudine S, T Capsules mg Zidovudine S, T Tablets 100 mg, 300 mg ADDED MEDICINES Stavudine+ S,T Tablets 30mg+ 150mg Lamivudine Zidovudine+ S,T Tablets 300mg+ Lamivudine+ 150mg+ Nevirapine 200mg 6.4.2.2 Non-nucleoside reverse transcriptase inhibitors Route of Administration/ Medicines Category Strengths Dosage Form 200 mg, Efavirenz S, T Capsules 600 mg Capsules 200 mg Nevirapine S, T Suspension 50 mg / 5 ml 6.4.2.3 Protease inhibitors Route of Administration/ Medicines Category Strengths Dosage Form Indinavir S, T Capsules 200 mg, 400 mg Nelfinavir S, T Capsules 250 mg Capsules 100 mg, Ritonavir S, T Syrup 400 mg / 5 ml Saquinavir S, T Capsules 200 mg Page 42 of 123  6.5 Antiprotozoal Medicines 6.5.1 Antiamoebic and Antigiardiasis medicines Route of Administration/ Medicines Category Strengths Dosage Form Diloxanide Furoate P,S,T Tablets 500 mg Metronidazole P,S,T Tablets 200 mg, 400 mg Injection 500 mg /100 ml 6.5.2 Antileishmaniasis medicines Route of Administration/ Medicines Category Strengths Dosage Form Amphotericin B S, T Injection 50 mg Pentamidine Isothionate S, T Injection 200 mg Sodium Stibogluconate S, T Injection 100 mg / ml 6.5.3 Antimalarial Medicines 6.5.3.1 For curative treatment Route of Administration/ Medicines Category Strengths Dosage Form Artesunate (To be used only in combination with P,S,T Tablets 50 mg Sulfadoxine + Pyrimethamine) Tablets 150 mg base Chloroquine phosphate Injection 40 mg / ml P,S,T Syrup 50 mg / 5 ml Primaquine P,S,T Tablets 2.5 mg, 7.5 mg Pyrimethamine P,S,T Tablets 25 mg P,S,T Tablets 300 mg Quinine sulphate ST Injection 300 mg / ml Sulfadoxine + Pyrimethamine P,S,T Tablets 500 mg + 25 mg Page 43 of 123  Medicines added Clindamycin S,T Tablet 150, 300mg 6.5.3.2 For prophylaxis Route of Administration/ Medicines Category Strengths Dosage Form Medicines added Mefloquine S,T Tablet 250 mg base 6.5.4 Antipneumocystosis and Antitoxoplasmosis medicines Route of Administration/ Medicines Category Strengths Dosage Form P,S,T Tablets 80 + 400 mg, Co-Trimoxazole 160+800 mg (Trimethoprim + Sulphamethoxazole) Suspension 40 + 200 mg / 5 ml Pentamidine Isothionate S, T Injection 200 mg Page 44 of 123  NLEM 2011 Section: 7 –Antimigraine medicines 7.1: For treatment of acute attack Route of Administration/ Medicines Category Strengths Dosage Form Acetyl Salicylic Acid P,S,T Tablets 300 - 350 mg Dihydroergotamine S, T Tablets 1 mg Paracetamol P,S,T Tablets 500 mg 7.2: For Prophylaxis Route of Administration/ Medicines Category Strengths Dosage Form Propranolol P,S,T Tablets 10 mg, 40 mg hydrochloride Page 45 of 123 Section: 8 –Antineoplastic, immunosuppressives and medicines used in palliative care 8.1: Immunosuppressive medicines Route of Administration/ Medicines Category Strengths Dosage Form Azathioprine T Tablets 50 mg 10 mg, 25 mg, Cyclosporine T Capsules 50 mg, 100 mg Concentrate for Injection 100 mg/ml 8.2: Cytotoxic medicines Route of Administration/ Medicines Category Strengths Dosage Form Actinomycin D T Injection 0.5 mg Alpha Interferon T Injection 3 million IU Bleomycin T Injection 15 mg Busulphan T Tablets 2 mg 10 mg / vial Cisplatin T Injection 50 mg / vial Tablets 50 mg, 200 mg Cyclophosphamide T Injection 500 mg 100 mg/vial Cytosine T Injection 500 mg/vial arabinoside 1000 mg/vial Danazol T Capsules 50 mg, 100 mg Doxorubicin T Injection 10 mg, 50 mg Capsules 100 mg Etoposide T Injection 100 mg/ 5 ml vial Page 46 of 123  Flutamide T Tablet 250 mg 5-Fluorouracil T Injection 250 mg / 5 ml Folinic Acid T Injection 3 mg / ml Gemcitabine 200 mg T Injection hydrochloride 1 gm L- Asparaginase T Injection 5000 KU. Melphalan T Tablet 2 mg, 5 mg Tablet 50 mg Mercaptopurine T Injection 100 mg / ml Tablet 2.5 mg Methotrexate T Injection 50 mg / ml Mitomycin-C T Injection 10 mg Paclitaxel T Injection 30 mg / 5 ml Procarbazine T Capsules 50 mg Vinblastine T Injection 10 mg sulphate Vincristine T Injection 1 mg / ml Added medicines Carboplatin T Injection 150 mg, 450 mg vial Dacarbazine T Injection 500 mg Daunorubicin T Injection 20 mg vial Ifosfamide T Injection 1 gm/2ml vial Mesna T Injection 200 mg Oxaliplatin T Injection 50 mg vial Imatinib T Tablets 100 mg, 400 mg Chlorambucil T Tablets 2 mg Page 47 of 123  8.3: Hormones and antihormones Route of Administration/ Medicines Category Strengths Dosage Form Tablets 5 mg Prednisolone S, T 20 mg, 25 mg (as Injection sodium phosphate or succinate) Raloxifene T Tablets 60 mg Tamoxifen T Tablets 10 mg, 20 mg Citrate 8.4: Medicines used in palliative care Route of Administration/ Medicines Category Strengths Dosage Form Morphine T Tablets 10 mg Sulphate Tablets 4 mg, 8 mg Ondansetron S, T Injection 2 mg/ml Syrup 2 mg/5 ml Added Medicines Filgrastim T Injection 1 ml vial Allopurinol T Tablets 100 mg Page 48 of 123  Section: 9 –Antiparkinsonism medicines Route of Administration/ Medicines Category Strengths Dosage Form Bromocriptine S, T Tablets 1.25 mg, 2.5 mg Mesylate Levodopa+ P,S,T Tablets 100 mg+10 mg Carbidopa 250 mg+25 mg 100 mg+25 mg Trihexyphenidyl P,S,T Tablets 2 mg Hydrochloride Page 49 of 123  Section: 10 –Medicines affecting the blood 10.1: Antianaemia medicines Route of Administration/ Medicines Category Strengths Dosage Form Cyanocobalamin P, S,T Injection 1 mg/ml Ferrous P,S,T Tablets Tablets equivalent to 60 Sulphate/ mg elemental iron Fumrate Oral solution 25mg elemental iron (as sulphate)/ml Folic Acid P,S,T Tablets 1 mg , 5mg Iron Dextran S, T Injection 50 mg iron/ml Pyridoxine P,S,T Tablets 10 mg 10.2: Medicines affecting coagulation Route of Administration/ Medicines Category Strengths Dosage Form 1000 IU/ml Heparin Sodium S, T Injection 5000 IU/ ml Protamine S, T Injection 10 mg/ml Sulphate Phytomenadione P, S, T Injection 10 mg/ml Warfarin sodium S, T Tablets 5 mg Added Medicines Enoxaparin T Injection 40mg, 60mg Page 50 of 123  Section: 11 –Blood products and Plasma substitutes 11.1: Plasma Substitutes Route of Administration/ Medicines Category Strengths Dosage Form Dextran-40 P,S,T Injection 10% Dextran-70 P,S,T Injection 6% Fresh frozen T Injection plasma Hydroxyethyl Starch S, T Injection 6% (Hetastarch) Polygeline S, T Injection 3.5% 11.2: Plasma fractions for specific use Route of Administration/ Medicines Category Strengths Dosage Form Albumin S, T Injection 5%, 20 % Cryoprecipitate S, T Injection Factor VIII S, T Injection Dried Concentrate Factor IX Complex (Coagulation S, T Injection Dried Factors II,VII, IX, X) Platelet Rich S, T Injection Plasma Page 51 of 123  Section: 12 –Cardiovascular medicines 12.1: Antianginal medicines Route of Administration/ Medicines Category Strengths Dosage Form 75mg, 100mg, Acetyl salicylic acid P,S,T Tablets 350 mg soluble/dispersible Diltiazem S, T Tablets 30 mg, 60 mg Glyceryl Trinitrate P,S,T Sublingual Tablets 0.5 mg Injection 5mg/ml Isosorbide 5 P,S,T Tablets 10 mg, Mononitrate/ 20 mg Dinitrate Tablets 25 mg, 50 mg Metoprolol P,S,T Injection 1mg/ml Added Medicines Clopidogrel T Tablets 75 mg 12.2: Antiarrhythmic medicines Route of Administration/ Medicines Category Strengths Dosage Form Adenosine S,T Injection 3 mg/ml 100 mg, 200 mg Amiodarone S, T Tablets 50 mg/ml (3 ml Injection ampoule) S, T Tablets 30 mg, 60 mg Diltiazem T Injection 5 mg/ ml Page 52 of 123  Esmolol T 10 mg / ml Injection Lignocaine S, T Injection 1%, 2% Hydrochloride Procainamide Tablets 250 mg T Hydrochloride Injection 100mg/ml Tablets 40 mg, 80 mg Verapamil S, T Injection 2.5mg/ml 12.3: Antihypertensive medicines Route of Administration/ Medicines Category Strengths Dosage Form 2.5 mg, Amlodipine P,S,T Tablets 5 mg 50mg, Atenolol P,S,T Tablets 100 mg Enalapril P,S,T Tablets 2.5 mg, 5mg Maleate T Injection 1.25mg/ml Losartan S, T Tablets 25 mg, Potassium 50 mg Methyldopa P,S, T Tablets 250 mg Capsules 5 mg, 10mg Tablets Nifedipine S, T 10mg, 20mg Sustained release tablets 10mg, 20mg or capsules Sodium T Injection 50 mg/ 5 ml Nitroprusside Added Medicines 12.5, Hydrochlorthiazide P,S,T Tablets 25 mg Page 53 of 123  12.4: Medicines used in heart failure Route of Administration/ Medicines Category Strengths Dosage Form Tablets 0.25 mg Digoxin S, T Injection 0.25 mg/ml Elixir 0.05 mg/ml Dobutamine S, T Injection 50 mg / ml Dopamine S,T Injection 40 mg / ml Hydrochloride 12.5: Antithrombotic medicines Route of Administration/ Medicines Category Strengths Dosage Form 75mg, 100mg, Acetyl salicylic acid P,S,T Tablets 350 mg soluble/dispersible S, T Injection 1000 IU /ml Heparin Sodium 5000 IU/ml 750,000 IU S, T Injection Streptokinase 15,00,000 IU T Injection 500,000 Urokinase IU/ml 10,00,000 IU/ml New Category - ADDED 12.6 Hypolipidemic Medicines Atorvastatin P,S,T Tablets 5 mg, 10 mg Page 54 of 123  Section: 13 –Dermatological medicines (Topical) 13.1: Antifungal medicines Route of Administration/ Medicines Category Strengths Dosage Form Miconazole P,S,T Ointment or Cream 2% 13.2: Antiinfective medicines Route of Administration/ Medicines Category Strengths Dosage Form Acyclovir S, T Cream 5% Framycetin P,S,T Cream 0.5% Sulphate Methylrosanilinium Chloride (Gentian P,S,T Aqueous solution 0.5% Violet) Neomycin + P,S,T Ointment 5 mg + 500 IU / g Bacitracin Povidone Iodine P,S,T Solution or Ointment 5% Silver P,S,T Cream 1% Sulphadiazine 13.3: Antiinflammatory and antipruritic medicines Route of Administration/ Medicines Category Strengths Dosage Form Betamethasone P,S,T Cream / Ointment 0.05% Dipropionate Calamine P,S,T Lotion 13.4: Astringent Medicines Route of Administration/ Medicines Category Strengths Dosage Form Zinc Oxide P,S,T Dusting Powder Page 55 of 123  13.5: Medicines affecting skin differentiation and proliferation Route of Administration/ Medicines